Autres langues ARS Pharmaceuticals, Inc.

Actions

SPRY

US82835W1080

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
9,75 ^USD	+3,07%		+16,77%	+77,92%

30/04	ARS Pharmaceuticals, Inc. soumet au CHMP de l'EMA sa réponse à la demande d'autorisation de mise sur le marché de Neffy (spray nasal à l'épinéphrine)	CI
30/04	Ars Pharmaceuticals, Inc. conclut un accord exclusif de licence et de distribution avec CSL Seqirus pour la commercialisation de Neffy en Australie et en Nouvelle-Zélande	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand	30/04
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	30/04
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	30/04
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	10/04
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21/03
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	18/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day	08/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day	07/03
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024	06/03
North American Morning Briefing : Stock Futures -2-	06/03
ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	27/02
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ARS Pharmaceuticals, Inc.

Actions

SPRY

US82835W1080

Autres langues

Filtres